肿瘤药学2025，Vol.15Issue(1)：21-31,11.DOI:10.3969/j.issn.2095-1264.2025.01.03
PARP抑制剂在卵巢癌治疗中的耐药机制及克服耐药策略的研究进展
Research progress of drug resistance mechanism of PARP inhibitors in ovarian cancer treatment and strategies to overcome drug resistance
郝静 1邓鹏 1刘诗妮 1陈剑锋 1谭静1
作者信息
- 1. 华南恶性肿瘤防治全国重点实验室/广东省恶性肿瘤临床医学研究中心/中山大学肿瘤防治中心,广东 广州,510060
- 折叠
摘要
Abstract
The poly(ADP-ribose)polymerase inhibitors(PARPi)represent a highly effective targeted therapeutic ap-proach for ovarian cancer.Various PARPi have been approved for the first-line treatment of ovarian cancer and mainte-nance therapy after recurrence.Despite their broad application prospects,the prominent issue of drug resistance remains a critical challenge.In recent years,studies related to the resistance mechanism of PARPi and strategies to overcome drug re-sistance have become a research focus both domestically and internationally.This article reviews the latest advancements in PARPi-based therapies for ovarian cancer and their resistance mechanism,aiming to provide insights and references for expanding the clinical application of PARPi.关键词
卵巢癌/PARP抑制剂/耐药Key words
Ovarian cancer/PARP inhibitors/Drug resistance分类
临床医学引用本文复制引用
郝静,邓鹏,刘诗妮,陈剑锋,谭静..PARP抑制剂在卵巢癌治疗中的耐药机制及克服耐药策略的研究进展[J].肿瘤药学,2025,15(1):21-31,11.
